KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. Its primary efforts include the development of safer, abuse resistant opioid pain relievers. KemPharm’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. The Company uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.